KI Innovations — Karolinska Institutet's University-to-Clinic Life-Science Spinout Pipeline

KI Innovations is the technology-transfer subsidiary of Karolinska Institutet Holding AB (KIHAB), the innovation-commercialisation company wholly owned by Karolinska Institutet, one of Europe's leading medical universities, headquartered in Solna next to the university campus.

Evaluate research disclosures from Karolinska Institutet and take selected projects from idea to funded company via its DRIVE incubator.

Since starting this work in 1996, KI Innovations has reviewed more than 1,400 academic innovations, created 40 startups and signed 35 licence agreements, according to independent life-sciences trade press coverage. Its incubator (branded DRIVE) now evaluates over 100 business proposals a year and launches roughly a dozen new companies annually.

Two of its portfolio companies, AnaCardio (heart failure) and Gesynta (endometriosis), have together raised more than SEK 500 million in investor funding and reached clinical-stage drug development. In February 2025, Vinnova (Sweden's government innovation agency) renewed its support with SEK 29.3 million in funding for 2025-2029.

The '40 startups / 35 licences since 1996' figure is a cumulative, self-reported total spanning nearly three decades and was not accompanied by a survival-rate or return-on-investment breakdown in the sources reviewed. Most spin-offs from any university incubator fail commercially, and the featured clinical-stage successes represent a small, favourable subset of the portfolio rather than the typical outcome.